Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls

Zhang, Xiaofen; Yang, Ziyao; Shi, Zhang; Zhu, Zhihao; Li, Cai; Du, Zhicheng; Zhang, Yiding; Wang, Zipeng; Jiao, Zhenrui; Tian, Xin; Zhang, Ji; Zhai, Wenlong; Kan, Quancheng

doi:10.1016/j.jsbmb.2020.105775

Cited by 28 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus far, CA19-9 was the most commonly used tumor marker for CCA, nevertheless, the forecasting performance of CA19-9 remains unsatisfactory(AUC = 0.881) [42], and histological diagnosis is the gold standard for diagnosing CCA. Non-invasive biomarkers for early detection and diagnosis of CCA have been an unmet need [2].…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Zhang

Jin

et al. 2021

SSRN Journal

View full text Add to dashboard Cite

BACKGROUNDThe liver-microbiome axis is implicated in the pathogenesis of hepatobiliary cancer, and the role of the gut microbiota in cholangiocarcinoma (CCA) remains unclear. METHODWe conducted a case-control study on the intestinal ora of 33 CCA patients and 47 cholelithiasis individuals. We performed 16S rRNA gene sequencing to identify disease-related gut microbiota and assess the potential of the intestinal microbiome as a non-invasive biomarker for CCA. RESULTWe found that gut microbiome of CCA patients had a signi cantly higher alpha diversity (Shannon and Observed species indices, p = 0.006 and p = 0.02, respectively) and an overall different microbial community composition (p = 0.032). The genus Muribaculaceae_unclassi ed was most strongly associated with CCA (p < 0.001). We put forward a disease predictive model including twelve intestinal microbiome genera distinguished CCA patients from CF patients with an area under curve (AUC) of approximately 0.93 (95%CI, 0.85-0.987). The forecasting performance of this model was better than CA19-9. Moreover, genera Ezakiella and Garciella were only observed among intrahepatic cholangiocarcinoma patients. Further, we assessed predicted functional modules alternations CCA patients and uncovered a microbiota pattern speci c to CCA. CONCLUSIONOur ndings provide evidence of the intestinal microbiome as a non-invasive biomarker for CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Zhang

Jin

et al. 2021

SSRN Journal

View full text Add to dashboard Cite

show abstract

“…Specific changes in the composition of bile can both induce and be suggestive of an underlying malignant process in the biliary tree (11,82,83). A reduction in total biliary bile acid content was noted by several groups as a unique feature in CCA, compared to other malignant (PDAC) and benign causes of biliary obstruction (76,(83)(84)(85).…”

Section: Metabolites and Proteinsmentioning

confidence: 99%

“…Secondly, the activation of receptors mediating these signalling pathways [i.e. G-protein coupled bile acid receptor 1 (GPBAR1) and sphingosine 1 phosphate receptor 2 (S1PR2), or nuclear factor kappa B (NF-kB)] in CCA tissue samples is enhanced (82,(86)(87)(88)(89). Furthermore, differences between serum/stool ratios of GCA and tauroursodeoxycholic acid (TUDCA), have been linked with a specific composition of intestinal microbiota (Lactobacillus, Actinomyces, Peptostreptococcaceae, and Alloscardovia) as a feature in iCCA vs. patients with liver cirrhosis, HCC, as well as compared to healthy subjects (90).…”

Section: Metabolites and Proteinsmentioning

confidence: 99%

Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum

et al. 2021

View full text Add to dashboard Cite

Cholangiocarcinoma is an uncommon and highly aggressive biliary tract malignancy with few manifestations until late disease stages. Diagnosis is currently achieved through a combination of clinical, biochemical, radiological and histological techniques. A number of reported cancer biomarkers have the potential to be incorporated into diagnostic pathways, but all lack sufficient sensitivity and specificity limiting their possible use in screening and early diagnosis. The limitations of standard serum markers such as CA19-9, CA125 and CEA have driven researchers to identify multiple novel biomarkers, yet their clinical translation has been slow with a general requirement for further validation in larger patient cohorts. We review recent advances in the diagnostic pathway for suspected CCA as well as emerging diagnostic biomarkers for early detection, with a particular focus on non-invasive approaches.

show abstract

“…Cholangiocarcinoma was thought to be related to bile acid metabolism[ 51 ]. Zhang et al [ 52 ] analyzed 329 plasma samples collected from the controls, benign biliary diseases, cholangiocarcinoma, gallbladder cancer, and HCC populations. Taurochenodeoxycholic acid and chenodeoxycholic acid played key roles in separating cholangiocarcinoma both from the healthy controls and from the HCC patients.…”

Section: Gi Cancer Diagnosis and Early Diagnosismentioning

confidence: 99%

Application of metabolomics in clinical and laboratory gastrointestinal oncology

Gao¹,

Huang²,

Fang³

et al. 2021

WJGO

View full text Add to dashboard Cite

Metabolites are versatile bioactive molecules. They are not only the substrates and/or the products of enzymatic reactions but also act as the regulators in the systemic metabolism. Metabolomics is a high-throughput analytical strategy to qualify or quantify as many metabolites as possible in the metabolomes. It is an indispensable part of systems biology. The leading techniques in this field are mainly based on mass spectrometry and nuclear magnetic resonance spectroscopy. The metabolomic analysis has gained wide use in bioscience fields. In the tumor research arena, metabolomics can be employed to identify biomarkers for prediction, diagnosis, and prognosis. Chemotherapeutic effect evaluation and personalized medicine decision-making can also benefit from metabolomic analysis of patient biofluid or biopsy samples. Many cell-level studies can help in disease exploration. In this review, the basic features and principles of varied metabolomic analysis are introduced. The value of metabolomics in clinical and laboratory gastrointestinal cancer studies is discussed, especially for mass spectrometry applications. Besides, combined use of metabolomics and other tools to solve problems in cancer practice is briefly illustrated. In summary, metabolomics paves a new way to explore cancerous diseases in the light of small molecules.

show abstract

Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls

Cited by 28 publications

References 34 publications

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum

Application of metabolomics in clinical and laboratory gastrointestinal oncology

Contact Info

Product

Resources

About